Wall Street Bets Chinese Stocks Will Extend Rally

BEIJING, Dec. 7, 2025 — Chinese equities posted significant gains this year, with the MSCI China Index rising 30% year-to-date, outpacing the S&P 500 by the widest margin since 2017. Global fund managers are increasingly optimistic, predicting the rally will extend into 2026, fueled by strong foreign capital inflows into strategic sectors.

AI Sector Draws Record Investment

Artificial intelligence has emerged as a magnet for overseas investors. Foreign capital inflows into Chinese AI startups reached $98 billion in 2025, a 48% increase from the previous year. Lower valuations compared to U.S. counterparts — roughly one-quarter the cost — present a compelling opportunity. Startups such as DeepSeek and AI2 Robotics have secured multiple funding rounds, while government support added $56 billion in public sector investment for infrastructure and R&D.

Biopharma Expansion Accelerates

Biopharma is now China’s fastest-growing FDI sector. In the first seven months of 2025, pledges totaled $4 billion, six times higher than in 2024. Major commitments include AstraZeneca’s $2.5 billion R&D hub in Beijing, alongside expansions by Novo Nordisk, Roche, Sanofi, and Eli Lilly. Regulatory liberalization — including foreign ownership in hospitals and eased restrictions on stem cells and gene therapy — has positioned biopharma as one-third of China’s total inward FDI, central to Beijing’s Healthy China 2030 strategy.

Robotics Industry Gains Momentum

China’s robotics sector continues rapid expansion, with robot density reaching 470 units per 10,000 workers in 2023, surpassing most global peers. Firms such as Unitree Robotics (valuation: $1.7 billion) and Siasun Robot & Automation are attracting foreign backing. Government initiatives under Made in China 2025 and a RMB 1-trillion venture capital fund are expected to drive annual growth of 11.39%, with the market projected to hit $13.9 billion by 2029.

Semiconductor Rally Leads Markets

Semiconductor stocks are at the forefront of the current rally. SMIC shares surged 185%, while Hua Hong Semiconductor jumped 304% year-to-date. Net foreign capital inflows into Chinese equities reached $4.6 billion in September 2025, the highest since late 2024. China now accounts for 42% of global semiconductor equipment spending and 30% of backend capacity in assembly and testing, bolstered by policy support and AI-driven demand.

Risks Remain

Despite strong momentum, challenges persist. Deflation risks and weak consumer demand weigh on growth, while geopolitical tensions and U.S. export controls on advanced chips slow progress. Capital controls and regulatory opacity continue to deter some foreign investors.

Outlook

Wall Street remains convinced of China’s essential role in global diversification and innovation. With AI, biopharma, robotics, and semiconductors attracting the bulk of foreign capital, analysts expect the rally to extend beyond 2026, positioning China as a global leader in next-generation industries.

References

- CNBC – Foreign investors warm to China’s cheaper AI valuations
- TechWire Asia – China AI investment hits $98B in 2025
- fDi Intelligence – China courts foreign biopharma firms in healthcare push
- AInvest – Rise of China’s Robotics Sector
- Yuan Trends – Semiconductor sector leads foreign capital inflows
- DBS Bank – China Semiconductor Industry Focus
- CNBC – Foreign investors eye Chinese tech again, but capital controls weigh